Clemens Muehlan

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Topics

Cognitive Impairment

Placebo Controlled

Top Venues

Clinical and translational science

Journal of sleep research

CPT: pharmacometrics & systems pharmacology

Clinical and experimental pharmacology & physiology

This page only lists publications with an associated author ORCID identifier.

Publications

Ingrid W Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop M A Van Gerven, Geert Jan Groeneveld, Rob G J A Zuiker
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clinical and translational science 17 (7) (2024)
Ingrid W Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop M A Van Gerven, Geert Jan Groeneveld, Rob G J A Zuiker
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clinical and translational science 17 (7) (2024)
Makoto Uchiyama, Kazuo Mishima, Tomoko Yagi, Tatsuya Yoshihara, Takashi Eto, Clemens Muehlan, Osamu Togo, Yuichi Inoue
Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: Results from phase 1 and 2 studies. Journal of sleep research (2024)
Ingrid W Koopmans, Daphne Geerse, Lara de Ridder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop M A Van Gerven, Geert Jan Groeneveld, Rob G J A Zuiker
The interactive walkway provides fit-for-purpose fall-risk biomarkers in the elderly: Comparison of zolpidem and suvorexant. Clinical and translational science 17 (7) (2024)
Clemens Muehlan, Catherine Roch, Cedric Vaillant, Jasper Dingemanse
The orexin story and orexin receptor antagonists for the treatment of insomnia. Journal of sleep research (2023)
Clemens Muehlan, Catherine Roch, Cedric Vaillant, Jasper Dingemanse
The orexin story and orexin receptor antagonists for the treatment of insomnia. Journal of sleep research (2023)
Clemens Muehlan, Catherine Roch, Cedric Vaillant, Jasper Dingemanse
The orexin story and orexin receptor antagonists for the treatment of insomnia. Journal of sleep research (2023)
Andreas Krause, Dominik Lott, Janneke M Brussee, Clemens Muehlan, Jasper Dingemanse
Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist. CPT: pharmacometrics & systems pharmacology (2022)
Benjamin Berger, Jasper Dingemanse, Giancarlo Sabattini, Stéphane Delahaye, Urs Duthaler, Clemens Muehlan, Stephan Krähenbühl
Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clinical pharmacokinetics 60 (10) (2021)
Benjamin Berger, Clemens Muehlan, Gernot Klein, Jasper Dingemanse
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment. Clinical and translational science 14 (6) (2021)
Benjamin Berger, Sander Brooks, Rob G J A Zuiker, Muriel Richard, Clemens Muehlan, Jasper Dingemanse
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects. CNS drugs 34 (12) (2020)
Isabelle Zenklusen, Clemens Muehlan, Ivan Ulc, Jiří Liška, Jasper Dingemanse
The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin. Clinical and experimental pharmacology & physiology 47 (11) (2020)
Clemens Muehlan, Cedric Vaillant, Isabelle Zenklusen, Stephan Kraehenbuehl, Jasper Dingemanse
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert opinion on drug metabolism & toxicology 16 (11) (2020)
Clemens Muehlan, Margaux Boehler, Sander Brooks, Rob G J A Zuiker, Joop van Gerven, Jasper Dingemanse
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. Journal of psychopharmacology (Oxford, England) 34 (3) (2019)